Stock screener

SVRA

Conviction 76HealthcareScan · Mon, Aug 10, 2026
SVRA$5.73-1.72%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 1.75M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Savara IncPHARMACEUTICAL PREPARATIONSwww.savarapharma.com ↗
Price5.73
Change-1.72%
Gap-0.51%
Rel volume0.94×
Avg volume1.69M
Avg $ vol9.44M
SMA 205.57
SMA 505.61
SMA 2005.46
Price vs 50+2.20%
Price vs 200+4.88%
MA stackbullish
50/200 cross—
Supertrenddown · 6.18
RSI (14)53
MACD hist0.03
MACD crossbull · 2d
Stoch %K / %D68 / 72
ADX (14)13
+DI / −DI25 / 18
RSI divergence—
MACD divergenceBullish
ATR %+4.70%
ADR %4.82%
52w high6.94
52w low2.58
From 52w high-17.44%
Above 52w low+122.09%
New 52w highNo
SqueezeOn · 3d
Bollinger width12.45%
%B0.73
Donchian pos65.09%
Donchian high6.03
Donchian low5.18
AVWAP (52w high)5.66
vs AVWAP high+1.22%
AVWAP (52w low)5.22
vs AVWAP low+9.75%
OBV trendDown
Chaikin MF (20)-0.25
Today vs 20d0.94×
Avg vol (14d)1.75M
Avg vol (20d)1.69M
Avg $ vol (20d)9.44M
Market cap1.17B
RS 3m (vs SPY)+7.29%
RS 6m (vs SPY)-1.13%
RS line new highNo
Trend template8/8
Technical rank56.8
1 week+7.50%
1 month-4.98%
3 months+9.56%
6 months+8.11%
1 year+117.87%
YTD+1.60%
P/E-9.88
P/B6.67
P/S—
P/FCF-11.62
EPS-0.5300
Div yield0.02%
ROE-67.51%
ROA-53.62%
Debt/Eq0.17
Current13.47
EV/EBITDA-9.51
Gross margin190.26%
Net margin—
Rev growth0.00%
EPS growth-23.94%
Price target11.17
Target upside94.94%
Analyst ratingBuy
Institutional109.88%
Ent. value1.17B
Revenue0
Net income-37.28M
Gross profit2.04M
Free cash flow-101.06M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out204.93M
Employees70
ListedMon, Nov 18, 1996
Free float130.57M
Float %64.2%
Short interest34.14M
Days to cover20.8d
Short volume71.3%
Squeeze score85 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.15 vs −$0.14
Last surprise-7.1% miss
Setup gradeA
Conviction76 / 100
Pattern quality—
Tech rank56.8 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance6.25
Support5.19
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in SVRA

All disclosures →
No recent disclosed trades by Congress in SVRA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in SVRA · 2 buys · 8 sells

InsiderSideShares
Lowrance David L
Chief Financial Officer · Common Stock · 2026-06-22
Sell394.53K
Lowrance David L
Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22
Exercise75K
Lowrance David L
Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22
Exercise129.35K
Lowrance David L
Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22
Exercise56.94K
Lowrance David L
Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22
Exercise87.65K
Lowrance David L
Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22
Exercise218.75K
Lowrance David L
Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22
Exercise12.5K
Lowrance David L
Chief Financial Officer · Common Stock · 2026-06-22
Exercise75K
Lowrance David L
Chief Financial Officer · Common Stock · 2026-06-22
Tax21.68K
Lowrance David L
Chief Financial Officer · Common Stock · 2026-06-22
Exercise129.35K

SEC filings

EDGAR filings in SVRA · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.